← Back to Search
Spectroscopic Magnetic Resonance Imaging of Glioma (MEGA-PRESS Trial)
Minneapolis, MN
N/A
Waitlist Available
Led By Clark Chen, MD, PhD
Research Sponsored by University of Minnesota
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 30 minutes
Awards & highlights
No Placebo-Only Group
Summary
The study is designed to develop and test new Magnetic Resonance Imaging methods that can improve the characterization of brain cancer and facilitate improved clinical care of these participants.
See full description
Eligible Conditions
- Gliomas
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 30 minutes
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~30 minutes
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
The number of brain cancer participants with IDH mutation status
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Brain tumor patients with GliomaExperimental Treatment1 Intervention
1. Men and women scheduled who are diagnosed with glioma who is seeking clinical care for their conditions at the UMN Masonic cancer center.
2. Passed the safety screen for MRI
3. Age 18 or older Participants will receive MEGA-PRESS sequence Magnetic Resonance Spectroscopy during their routined schedule standard of care MRI.
Find a Location
Closest Location:University of Minnesota· Minneapolis, MN· 626 miles
Who is running the clinical trial?
University of MinnesotaLead Sponsor
1,456 Previous Clinical Trials
1,625,097 Total Patients Enrolled
Clark Chen, MD, PhDPrincipal InvestigatorUniversity of Minnesota